NCT00809965: An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome |
|
|
| Completed | 3 | 15526 | Europe, Canada, Japan, US, RoW | Rivaroxaban 2.5 mg, Rivaroxaban 5 mg, Placebo, Standard of care | Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Bayer | Acute Coronary Syndrome, Myocardial Infarction, Myocardial Ischemia, Unstable Angina | 09/11 | 09/11 | | |
